Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) Acute Intermittent Porphyria Market Research Report 2019-2025

Request for Sample of this report
Buy now
  • 1.1 Research Scope
  • 1.2 Market Segmentation
  • 1.3 Research Objectives
  • 1.4 Research Methodology
    • 1.4.1 Research Process
    • 1.4.2 Data Triangulation
    • 1.4.3 Research Approach
    • 1.4.4 Base Year
  • 1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
    • 1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
    • 1.5.2 Covid-19 Impact: Commodity Prices Indices
    • 1.5.3 Covid-19 Impact: Global Major Government Policy
  • 1.6 The Covid-19 Impact on Acute Intermittent Porphyria Industry
  • 1.7 COVID-19 Impact: Acute Intermittent Porphyria Market Trends

    • 2 Global Acute Intermittent Porphyria Quarterly Market Size Analysis

    • 2.1 Acute Intermittent Porphyria Business Impact Assessment - COVID-19
      • 2.1.1 Global Acute Intermittent Porphyria Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
    • 2.2 Global Acute Intermittent Porphyria Quarterly Market Size 2020-2021
    • 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
      • 2.3.1 Drivers
      • 2.3.2 Restraints
      • 2.3.3 Opportunities
      • 2.3.4 Challenges

    3 Quarterly Competitive Assessment, 2020

    • 3.1 By Players, Global Acute Intermittent Porphyria Quarterly Market Size, 2019 VS 2020
    • 3.2 By Players, Acute Intermittent Porphyria Headquarters and Area Served
    • 3.3 Date of Key Players Enter into Acute Intermittent Porphyria Market
    • 3.4 Key Players Acute Intermittent Porphyria Product Offered
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Impact of Covid-19 on Acute Intermittent Porphyria Segments, By Type

    • 4.1 Introduction
      • 1.4.1 Gonadotropin-Releasing Hormone Analogues
      • 1.4.2 Prophylactic Hematin Infusions
    • 4.2 By Type, Global Acute Intermittent Porphyria Market Size, 2019-2021

    5 Impact of Covid-19 on Acute Intermittent Porphyria Segments, By Application

    • 5.1 Overview
      • 5.5.1 Hospitals & Clinics
      • 5.5.2 Research Centers
    • 5.2 By Application, Global Acute Intermittent Porphyria Market Size, 2019-2021
      • 5.2.1 By Application, Global Acute Intermittent Porphyria Market Size by Application, 2019-2021

    6 Geographic Analysis

    • 6.1 Introduction
    • 6.2 North America
      • 6.2.1 Macroeconomic Indicators of US
      • 6.2.2 US
      • 6.2.3 Canada
    • 6.3 Europe
      • 6.3.1 Macroeconomic Indicators of Europe
      • 6.3.2 Germany
      • 6.3.3 France
      • 6.3.4 UK
      • 6.3.5 Italy
    • 6.4 Asia-Pacific
      • 6.4.1 Macroeconomic Indicators of Asia-Pacific
      • 6.4.2 China
      • 6.4.3 Japan
      • 6.4.4 South Korea
      • 6.4.5 India
      • 6.4.6 ASEAN
    • 6.5 Rest of World
      • 6.5.1 Latin America
      • 6.5.2 Middle East and Africa

    7 Company Profiles

    • 7.1 Dahaner
      • 7.1.1 Dahaner Business Overview
      • 7.1.2 Dahaner Acute Intermittent Porphyria Quarterly Revenue, 2020
      • 7.1.3 Dahaner Acute Intermittent Porphyria Product Introduction
      • 7.1.4 Dahaner Response to COVID-19 and Related Developments
    • 7.2 Roche
      • 7.2.1 Roche Business Overview
      • 7.2.2 Roche Acute Intermittent Porphyria Quarterly Revenue, 2020
      • 7.2.3 Roche Acute Intermittent Porphyria Product Introduction
      • 7.2.4 Roche Response to COVID-19 and Related Developments
    • 7.3 Bio-Rad Laboratories
      • 7.3.1 Bio-Rad Laboratories Business Overview
      • 7.3.2 Bio-Rad Laboratories Acute Intermittent Porphyria Quarterly Revenue, 2020
      • 7.3.3 Bio-Rad Laboratories Acute Intermittent Porphyria Product Introduction
      • 7.3.4 Bio-Rad Laboratories Response to COVID-19 and Related Developments
    • 7.4 Siemens
      • 7.4.1 Siemens Business Overview
      • 7.4.2 Siemens Acute Intermittent Porphyria Quarterly Revenue, 2020
      • 7.4.3 Siemens Acute Intermittent Porphyria Product Introduction
      • 7.4.4 Siemens Response to COVID-19 and Related Developments
    • 7.5 ARKRAY
      • 7.5.1 ARKRAY Business Overview
      • 7.5.2 ARKRAY Acute Intermittent Porphyria Quarterly Revenue, 2020
      • 7.5.3 ARKRAY Acute Intermittent Porphyria Product Introduction
      • 7.5.4 ARKRAY Response to COVID-19 and Related Developments
    • 7.6 Sysmex Corporation
      • 7.6.1 Sysmex Corporation Business Overview
      • 7.6.2 Sysmex Corporation Acute Intermittent Porphyria Quarterly Revenue, 2020
      • 7.6.3 Sysmex Corporation Acute Intermittent Porphyria Product Introduction
      • 7.6.4 Sysmex Corporation Response to COVID-19 and Related Developments
    • 7.7 ACON Laboratories
      • 7.7.1 ACON Laboratories Business Overview
      • 7.7.2 ACON Laboratories Acute Intermittent Porphyria Quarterly Revenue, 2020
      • 7.7.3 ACON Laboratories Acute Intermittent Porphyria Product Introduction
      • 7.7.4 ACON Laboratories Response to COVID-19 and Related Developments

    8 Key Findings

      9 Appendix

      • 9.1 About US

      This report covers market size and forecasts of Acute Intermittent Porphyria, including the following market information:
      Global Acute Intermittent Porphyria Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million)
      Global Acute Intermittent Porphyria Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million)
      Global Acute Intermittent Porphyria Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million)
      Global Acute Intermittent Porphyria Market Size by Company, 2019- 2020 (quarterly data), (US$ Million)

      Key market players
      Major competitors identified in this market include Dahaner, Roche, Bio-Rad Laboratories, Siemens, ARKRAY, Sysmex Corporation, ACON Laboratories, etc.

      Based on the Region:
      Asia-Pacific (China, Japan, South Korea, India and ASEAN)
      North America (US and Canada)
      Europe (Germany, France, UK and Italy)
      Rest of World (Latin America, Middle East & Africa)

      Based on the Type:
      Gonadotropin-Releasing Hormone Analogues
      Prophylactic Hematin Infusions

      Based on the Application:
      Hospitals & Clinics
      Research Centers

      Buy now